Black Rock Inc. Alaunos Therapeutics, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.04 - $0.13 $65,332 - $212,331	-1,633,321 Reduced 32.86%	3,336,911 $233,000
Q3 2023 Nov 13, 2023	SELL	$0.12 - $0.5 $12,257 - $51,074	-102,148 Reduced 2.01%	4,970,232 $646,000
Q2 2023 Aug 11, 2023	SELL	$0.43 - $0.65 $6,565 - $9,924	-15,269 Reduced 0.3%	5,072,380 $2.59 Million
Q1 2023 May 12, 2023	SELL	$0.46 - $0.81 $159,015 - $280,004	-345,685 Reduced 6.36%	5,087,649 $3.21 Million
Q4 2022 Feb 13, 2023	BUY	$0.5 - $261.0 $121,646 - $63.5 Million	243,292 Added 4.69%	5,433,334 $3.53 Million
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $49,667 - $15.4 Million	-47,757 Reduced 0.91%	5,190,042 $8.93 Million
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $4.7 Million - $14.2 Million	-11,466,908 Reduced 68.64%	5,237,799 $6.5 Million
Q1 2022 May 12, 2022	SELL	$0.62 - $1.17 $37,364 - $70,510	-60,265 Reduced 0.36%	16,704,707 $10.9 Million
Q4 2021 Feb 10, 2022	SELL	$1.09 - $1.89 $186,119 - $322,721	-170,752 Reduced 1.01%	16,764,972 $18.3 Million
Q3 2021 Nov 09, 2021	BUY	$1.44 - $2.73 $782,688 - $1.48 Million	543,534 Added 3.32%	16,935,724 $30.8 Million
Q2 2021 Aug 11, 2021	BUY	$2.63 - $3.67 $43.1 Million - $60.2 Million	16,392,190 New	16,392,190 $43.3 Million

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.